Oligonucleotide conjugated multi-functional adeno-associated viruses

Scientific Reports

Volumn 8, Issue 1, 2018, Pages

  Katrekar, Dhruva ^a   Moreno, Ana M ^a   Chen, Genghao ^a   Worlikar, Atharv ^a   Mali, Prashant ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CAPSID PROTEIN; NEUTRALIZING ANTIBODY; OLIGONUCLEOTIDE;

ANIMAL; BLOOD; CHEMISTRY; CLICK CHEMISTRY; DEPENDOPARVOVIRUS; GENE THERAPY; GENE VECTOR; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; GENETICS; HEK293 CELL LINE; HUMAN; IMMUNOLOGY; PIG; PROCEDURES;

AMINO ACIDS; ANIMALS; ANTIBODIES, NEUTRALIZING; CAPSID PROTEINS; CLICK CHEMISTRY; CRISPR-ASSOCIATED PROTEIN 9; DEPENDOVIRUS; GENETIC THERAPY; GENETIC VECTORS; HEK293 CELLS; HUMANS; OLIGONUCLEOTIDES; SWINE; TRANSDUCTION, GENETIC; TRANSFECTION;

EID: 85043279883     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-018-21742-x     Document Type: Article

References (55)

1. Srivastava, A., Lusby, E. W. & Berns, K. I. Nucleotide sequence and organization of the adeno-associated virus 2 genome. J. Virol. 45, 555-64 (1983).
2. Atchison, R. W., Casto, B. C. & Hammon, W. M. Adenovirus-Associated Defective Virus Particles. Science (80-.). 149 (1965).
3. Bowles, D. E. et al. Phase 1 Gene Therapy for Duchenne Muscular Dystrophy Using a Translational Optimized AAV Vector. Mol. Ther. 20, 443-455 (2012).
4. Stroes, E. S. et al. Intramuscular Administration of AAV1-Lipoprotein LipaseS447X Lowers Triglycerides in Lipoprotein Lipase-Deficient Patients. Arterioscler. Thromb. Vasc. Biol. 28, 2303-2304 (2008).
5. Carpentier, A. C. et al. Effect of Alipogene Tiparvovec (AAV1-LPL(S447X)) on Postprandial Chylomicron Metabolism in Lipoprotein Lipase-Deficient Patients. J. Clin. Endocrinol. Metab. 97, 1635-1644 (2012).
6. Nathwani, A. C. et al. Adenovirus-Associated Virus Vector-Mediated Gene Transfer in Hemophilia B. N. Engl. J. Med. 365, 2357-2365 (2011).
7. Manno, C. S. et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 101 (2003).
8. Manno, C. S. et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med. 12, 342-347 (2006).
9. Dong, J.-Y., Fan, P.-D. & Frizzell, R. A. Quantitative Analysis of the Packaging Capacity of Recombinant Adeno-Associated Virus. Hum. Gene Ther. 7, 2101-2112 (1996).
10. Boutin, S. et al. Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV Vectors. Hum. Gene Ther. 21, 704-712 (2010).
11. Erles, K., Sebökovà, P. & Schlehofer, J. R. Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV). J. Med. Virol. 59, 406-11 (1999).
12. Calcedo, R., Vandenberghe, L., Gao, G., Lin, J. & Wilson, J. Worldwide Epidemiology of Neutralizing Antibodies to Adeno-Associated Viruses. J. Infect. Dis. 199, 381-390 (2009).
13. Halbert, C. L. et al. Prevalence of Neutralizing Antibodies Against Adeno-Associated Virus (AAV) Types 2, 5, and 6 in Cystic Fibrosis and Normal Populations: Implications for Gene Therapy Using AAV Vectors. Hum. Gene Ther. 17, 440-447 (2006).
14. Zincarelli, C., Soltys, S., Rengo, G. & Rabinowitz, J. E. Analysis of AAV Serotypes 1-9 Mediated Gene Expression and Tropism in Mice After Systemic Injection. Mol. Ther. 16, 1073-1080 (2008).
15. Aslanidi, G. V. et al. Optimization of the Capsid of Recombinant Adeno-Associated Virus 2 (AAV2) Vectors: The Final Threshold? PLoS One 8, e59142 (2013).
16. Ried, M. U., Girod, A., Leike, K., Büning, H. & Hallek, M. Adeno-associated virus capsids displaying immunoglobulin-binding domains permit antibody-mediated vector retargeting to specific cell surface receptors. J. Virol. 76, 4559-4566 (2002).
17. Shi, W., Arnold, G. S. & Bartlett, J. S. Insertional mutagenesis of the adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors targeted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697-711 (2001).
18. Wu, P. et al. Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635-8647 (2000).
19. Kotterman, M. A. & Schaffer, D. V. Engineering adeno-associated viruses for clinical gene therapy. Nat. Rev. Genet. 15, 445-51 (2014).
20. Maheshri, N., Koerber, J. T., Kaspar, B. K. & Schaffer, D. V. Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. Nat. Biotechnol. 24, 198-204 (2006).
21. Perabo, L. et al. Combinatorial engineering of a gene therapy vector: directed evolution of adeno-associated virus. J. Gene Med. 8, 155-162 (2006).
22. Deverman, B. E. et al. Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. 34 (2016).
23. Zinn, E. et al. In Silico Reconstruction of the Viral Evolutionary Lineage Yields a Potent Gene Therapy Vector. Cell Rep. 12, 1056-1068 (2015).
24. Zheng, Y. et al. Broadening the versatility of lentiviral vectors as a tool in nucleic acid research via genetic code expansion. Nucleic Acids Res. 43, e73 (2015).
25. Guenther, C. M. et al. Synthetic virology: engineering viruses for gene delivery. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 6, 548-58 (2014).
26. Horowitz, E. D., Weinberg, M. S. & Asokan, A. Glycated AAV Vectors: Chemical Redirection of Viral Tissue Tropism. Bioconjug. Chem. 22, 529-532 (2011).
27. Kelemen, R. E. et al. A Precise Chemical Strategy To Alter the Receptor Specificity of the Adeno-AssociatedVirus. Angew. Chemie-Int. Ed. 55, 1-6 (2016).
28. Münch, R. C. et al. Displaying high-affinity ligands on adeno-associated viral vectors enables tumor cell-specific and safe gene transfer. Mol. Ther. 21, 109-18 (2013).
29. Xie, Q. et al. The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405-10410 (2002).
30. Furter, R. Expansion of the genetic code: Site-directed p-fluoro-phenylalanine incorporation in Escherichia coli. Protein Sci. 7, 419-426 (1998).
31. Wang, L., Brock, A., Herberich, B. & Schultz, P. G. Expanding the Genetic Code of Escherichia coli. Science (80-.). 292 (2001).
32. Chatterjee, A., Xiao, H., Bollong, M., Ai, H. & Schultz, P. G. Efficient viral delivery system for unnatural amino acid mutagenesis in mammalian cells. Proc. Natl. Acad. Sci. 110, 11803-11808 (2013).
33. Schmied, W. H., Elsa, S. J., Uttamapinant, C. & Chin, J. W. Efficient Multisite Unnatural Amino Acid Incorporation in Mammalian Cells via Optimized Pyrrolysyl tRNA Synthetase/tRNA Expression and Engineered eRF1. J. Am. Chem. Soc. 136, 15577-15583 (2014).
34. Elsässer, S. J., Ernst, R. J., Walker, O. S. & Chin, J. W. Genetic code expansion in stable cell lines enables encoded chromatin modification. Nat. Methods 13, 158-164 (2016).
35. Huisgen, R., Szeimies, G. & Mobius, L. 1.3-Dipolare Cycloadditionen, XXXII. Kinetik der Additionen organischer Azide an CC-Mehrfachbindungen. Chem. Ber. 100, 2494-2507 (1967).
36. Rostovtsev, V. V., Green, L. G., Fokin, V. V. & Sharpless, K. B. A Stepwise Huisgen Cycloaddition Process: Copper(I)-Catalyzed Regioselective 'Ligation' of Azides and Terminal Alkynes. Angew. Chemie 114, 2708-2711 (2002).
37. Lerch, T. F. et al. Structure of AAV-DJ, a Retargeted Gene Therapy Vector: Cryo-Electron Microscopy at 4.5Å resolution. Structure 20, 1310-1320 (2013).
38. Grimm, D. et al. In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. J. Virol. 82, 5887-911 (2008).
39. Lee, G. K., Maheshri, N., Kaspar, B. & Schaffer, D. V. PEG Conjugation Moderately Protects Adeno-Associated Viral Vectors Against Antibody Neutralization. Biotechnol. Bioeng. 92, 24-34 (2005).
40. Fitzpatrick, Z., Crommentuijn, M. H. W., Mu, D. & Maguire, C. A. Naturally enveloped AAV vectors for shielding neutralizing antibodies and robust gene delivery in vivo. Biomaterials 35, 7598-7609 (2014).
41. Rapti, K. et al. Neutralizing Antibodies Against AAV Serotypes 1, 2, 6, and 9 in Sera of Commonly Used Animal Models. Mol. Ther. 20, 73-83 (2009).
42. Truong, D. J. J. et al. Development of an intein-mediated split-Cas9 system for gene therapy. Nucleic Acids Res. 43, 6450-6458 (2015).
43. Leong Chew, W. et al. A multifunctional AAV-CRISPR-Cas9 and its host response. Nat. Methods 13, 868-874 (2016).
44. Yu, C. et al. Novel Aptamer-Nanoparticle Bioconjugates Enhances Delivery of Anticancer Drug to MUC1-Positive Cancer Cells In Vitro. PLoS One 6, e24077 (2011).
45. Hu, Y. et al. Novel MUC1 Aptamer Selectively Delivers Cytotoxic Agent to Cancer Cells In Vitro. PLoS One 7, e31970 (2012).
46. Xiong, X. et al. DNA Aptamer-MediatedCell Targeting. Angew. Chemie Int. Ed. 52, 1472-1476 (2013).
47. Tong, G. J., Hsiao, S. C., Carrico, Z. M. & Francis, M. B. Viral Capsid DNA Aptamer Conjugates as Multivalent Cell Targeting Vehicles. https://doi.org/10.1021/ja903857f.
48. Rothemund, P. W. K. Folding DNA to create nanoscale shapes and patterns. Nature 440, 297-302 (2006).
49. Ke, Y., Ong, L. L., Shih, W. M. & Yin, P. Three-Dimensional Structures Self-Assembled from DNA Bricks. Science (80-.). 338 (2012).
50. Dietz, H., Douglas, S. M. & Shih, W. M. Folding DNA into Twisted and Curved Nanoscale Shapes. Science (80-.). 325 (2009).
51. Douglas, S. M. et al. Self-assembly of DNA into nanoscale three-dimensional shapes. Nature 459, 414-8 (2009).
52. Grieger, J. C., Choi, V. W. & Samulski, R. J. Production and characterization of adeno-associated viral vectors. Nat. Protoc. 1, 1412-1428 (2006).
53. Guell, M., Yang, L. & Church, G. M. Genome editing assessment using CRISPR Genome Analyzer (CRISPR-GA). Bioinformatics 30, 2968-2970 (2014).
54. Nicholas, J. A., Jennifer, A. P. & Bertozzi, C. R. A Strain-Promoted [3 + 2] Azide-Alkyne Cycloaddition for Covalent Modification of Biomolecules in Living Systems. https://doi.org/10.1021/JA044996F (2004).
55. Mali, P. et al. Barcoding cells using cell-surface programmable DNA-binding domains. Nat. Methods 10, 403-6 (2013).